103 results
8-K/A
EX-99.2
LSTA
Lisata Therapeutics Inc
4 Oct 22
Other Events
4:42pm
could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment.
If Cend fails to comply with environmental … on the success of its business.
Cend is subject to numerous environmental, health and safety laws and regulations, including those governing laboratory
424B3
LSTA
Lisata Therapeutics Inc
29 Jul 22
Prospectus supplement
4:06pm
with environmental, health and safety laws and regulations, it could become subject to fines or penalties or incur costs that could have a material … adverse effect on the success of its business.
Cend is subject to numerous environmental, health and safety laws and regulations, including those
8-K
EX-2.1
1s32h8d5 yl
27 Apr 22
Caladrius Biosciences and Cend Therapeutics Announce
7:05am
8-K
EX-10.1
zc6k5h2myn4
4 Jun 21
Entry into a Material Definitive Agreement
4:44pm
D
w6r1sj8ix4z3t0d1bk
1 Feb 21
$25M in equity / options / securities to be acquired, sold $25M, 23 investors
12:53pm
8-K
EX-10.1
276j12 p41ttkw7enh39
25 Jan 21
Caladrius Biosciences Announces $25.0 Million Private Placement
4:01pm
D
rldd858
27 Jul 20
$2M in options / securities to be acquired, sold $2M, 3 investors
9:28am
8-K
EX-10.1
3vpp8y
10 Jul 20
Entry into a Material Definitive Agreement
4:41pm
D
yi2vftmkdpn
5 Jun 20
$2.15M in options / securities to be acquired, sold $2.15M, 6 investors
12:23pm
8-K
EX-10.1
20gtv2kke v8riw8rd25
26 May 20
Caladrius Biosciences Announces $4.3 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
8:02am
D
bm2mj5fcx 46htc
12 May 20
$2.43M in options / securities to be acquired, sold $2.43M, 5 investors
1:44pm
8-K
EX-10.1
iq125a qevfe
24 Apr 20
Caladrius Biosciences Announces $5.0 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules
4:02pm
8-K
EX-10.1
v36x5z
14 Mar 19
Caladrius Biosciences Reports 2018 Fourth Quarter and Year End Financial Results
4:18pm